Radium-223

Dr Chris Parker carried out the key registration phase III trial from The Royal Marsden that led to this drug's approval. The trial of 921 patients, published in the New England Journal of Medicine, showed that treatment with radioactive radium-223 gave men with late-stage prostate cancer longer overall survival and a better quality of life.